Education
About Us
Working with TipRanks
Follow Us
BNB Plus (BNBX)
NASDAQ:BNBX
BNBX Stock Chart & Stats
$1.48
--
Market closed
$1.48
--
Day’s Range― - ―
52-Week Range$0.61 - $111.75
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.96M
Market Cap
$4.02M
Enterprise Value-$1.45M
Total Cash (Recent Filing)$2.45M
Total Debt (Recent Filing)$48.86K
Price to Earnings (P/E)―
Beta2.95
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.08
Shares Outstanding5,447,469
10 Day Avg. Volume46,292
30 Day Avg. Volume1,955,224
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.87
Price to Sales (P/S)0.94
P/FCF Ratio-0.16
Enterprise Value/Market Cap-0.36
Enterprise Value/Revenue-0.71
Enterprise Value/Gross Profit-3.05
Enterprise Value/Ebitda0.06
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-82.5
Revenue Forecast (FY)$7.40M
Bulls Say, Bears Say
Bulls Say
GMP Manufacturing ScaleGMP certification creates durable operational capability to manufacture DNA at commercial scale, enabling contract production for clinical customers. This reduces technical and supply risk, supports higher-margin GMP revenue streams, and strengthens the firm's ability to convert R&D projects into recurring commercial sales over time.
LineaRx Strategic Pivot And PipelineRefocusing on LineaRx and a growing project backlog creates structural revenue potential from enzymatically produced DNA services and clinical customers. Multiple clinic-bound projects imply multi-year service relationships and validation that can drive steady, higher-value sales as clients progress through development stages.
Low Financial LeverageVery low debt levels materially reduce short-term solvency pressure and interest burden, giving management flexibility to execute the LineaRx pivot and invest in commercialization. This balance-sheet cushion lengthens runway compared with highly leveraged peers, supporting strategic execution while fundraising options are considered.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow indicate the company is burning cash faster than it generates it, requiring ongoing external financing. That dependency can dilute shareholders, limit investment in commercialization, and constrain the firm's ability to scale LineaRx without fresh capital over the 2–6 month horizon and beyond.
Declining Revenue And Margin CompressionA meaningful revenue decline combined with lower gross margin signals weaker demand, pricing pressure, or rising production costs. Those structural headwinds reduce operating leverage and make sustainable profitability harder to achieve even after cost cuts, undermining the long-term financial recovery plan tied to LineaRx scaling.
Going-concern And Capital NecessityAn explicit going-concern disclosure is a durable governance and financing risk: the company must secure capital or materially boost cash generation. This constraint increases execution risk, potential dilution, and management distraction, affecting strategic initiatives and the timeline for achieving self-sustaining operations.
BNB Plus News
BNBX FAQ
What was BNB Plus’s price range in the past 12 months?
BNB Plus lowest stock price was $0.60 and its highest was $111.75 in the past 12 months.
What is BNB Plus’s market cap?
BNB Plus’s market cap is $4.02M.
When is BNB Plus’s upcoming earnings report date?
BNB Plus’s upcoming earnings report date is May 07, 2026 which is in 62 days.
How were BNB Plus’s earnings last quarter?
BNB Plus released its earnings results on Feb 05, 2026. The company reported -$2.083 earnings per share for the quarter, missing the consensus estimate of N/A by -$2.083.
Is BNB Plus overvalued?
According to Wall Street analysts BNB Plus’s price is currently Overvalued.
Does BNB Plus pay dividends?
BNB Plus does not currently pay dividends.
What is BNB Plus’s EPS estimate?
BNB Plus’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BNB Plus have?
BNB Plus has 5,447,469 shares outstanding.
What happened to BNB Plus’s price movement after its last earnings report?
BNB Plus reported an EPS of -$2.083 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -31.746%.
Which hedge fund is a major shareholder of BNB Plus?
Currently, no hedge funds are holding shares in BNBX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BNB Plus
BNB Plus Corp. is a biotechnology company, which engages in the development and commercialization of technologies to produce and detect deoxyribonucleic acid and ribonucleic acid. It operates through the following segments: Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment consists of the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNAP for use in the production of mRNA therapeutics. The MDx Testing Services segment develops clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment is involved in the detection of DNA for industrial supply chains and security services. The company was founded in 1983 and is headquartered in Stony Brook, NY.
Technical Analysis
ENDRA Life Sciences
―
Intelligent Bio Solutions
―
iSpecimen
―
BioNexus Gene Lab Corp
―
Mainz Biomed B.V.
―
Ownership Overview
3.10% Insiders
0.06% Mutual Funds
4.45% Other Institutional Investors
92.38% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---